DOI:
10.1055/s-00000045
Der Nuklearmediziner
Ausgabe 02 ·
Volume 32 ·
Juni 2009
DOI: 10.1055/s-002-18774
Editorial
99
Nicht-FDG-PET
101
Kuwert, T.;
Prante, O.;
Meyer, G.:
Legal Aspects of the Production and Application of Radiopharmaceuticals in Germany
105
Reske, S. N.:
Current Status of Multimodal Molecular Imaging of Prostate Cancer
131
Beuthien-Baumann, B.:
18F-DOPA-PET in Neuroendocrine Tumours (NET)
135
Langen, K.-J.;
Stoffels, G.:
O-(2-[18F]Fluorethyl)-L-Tyrosine in the Diagnostics of Brain Tumors
142
Berding, G.:
11C-Methionine PET in Neurooncology
149
Freudenberg, L. S.;
Jentzen, W.;
Brandau, W.;
Stahl, A.;
Bockisch, A.:
Iodine-124 PET(/CT) in Differentiated Thyroid Cancer
154
Buck, A. K.;
Herrmann, K.;
Dechow, T.;
Graf, N.;
Schwaiger, M.;
Wester, H. J.:
Molecular Imaging of Proliferation with [18F]FLT-PET
164
Bares, R.;
Reischl, G.;
Eschmann, S.-M.:
Hypoxia Imaging
170
Drzezga, A.:
Amyloid-Plaque Imaging in Diagnosis of Dementia
178
Lindner, O.;
Burchert, W.:
Molecular Cardiac PET besides FDG Viability Imaging
CME Beitrag
115
Baum, R. P.;
Prasad, V.;
Hörsch, D.:
Molecular Imaging of Neuroendocrine Tumors Using 68Ga-Labeled Peptides (Somatostatin Receptor PET/CT)
